Milosz Jaroslaw Jaguszewski

Milosz Jaroslaw Jaguszewski

Auto-generated profile, based on publicly available information

Milosz Jaroslaw Jaguszewski

1st Department of Cardiology, Medical University of Gdansk, Poland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
BFBartosz Fialek
Bartosz Fialek
MPMichal Pruc
Michal Pruc
JSJacek Smereka
Jacek Smereka
RJRafal Daniel Jas
Rafal Daniel Jas
MRMansur Rahnama
Mansur Rahnama
Lukasz SzarpakLukasz Szarpak
Lukasz Szarpak
Background: This meta-analysis outlines the role of elevated lactate dehydrogenase (LDH) levels in assessing the severity of coronavirus disease 2019 (COVID-19). Methods: The current study was designed as a systematic review and meta-analysis. Embase, PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials were searched to identify the usefulness of LDH as a marker of COVID-19 severity. All extracted data were analyzed using RevMan V.5.4 or STATA V.14 software. Results: A total of 264 records were selected for this meta-analysis. Pooled analysis showed that LDH levels were statistically significantly lower in the group of survivors compared to patients who died in hospital (standardized mean differences [SMD] = –3.10; 95% confidence interval [CI]: –3.40 to –2.79; I2 = 99%; p < 0.001). Lower LDH levels were observed in non-severe groups compared to severe course of COVID-19 (SMD = –2.38; 95% CI: –2.61 to –2.14; I2 = 99%; p < 0.001). The level of LDH was statistically significantly lower in the severe group compared to the critical group (SMD = –1.48; 95% CI: –2.04 to –0.92; I2 = 98%; p < 0.001). Patients who did not require treatment in the intensive care unit (ICU) showed significantly lower levels of LDH compared to patients who required treatment in the ICU (SMD = –3.78; 95% CI: –4.48 to –3.08; I2 = 100%; p < 0.001). Conclusions: This meta-analysis showed that elevated LDH was associated with a poor outcome in COVID-19. Background: This meta-analysis outlines the role of elevated lactate dehydrogenase (LDH) levels in assessing the severity of coronavirus disease 2019 (COVID-19). Methods: The current study was designed as a systematic review and meta-analysis. Embase, PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials were searched to identify the usefulness of LDH as a marker of COVID-19 severity. All extracted data were analyzed using RevMan V.5.4 or STATA V.14 software. Results: A total of 264 records were selected for this meta-analysis. Pooled analysis showed that LDH levels were statistically significantly lower in the group of survivors compared to patients who died in hospital (standardized mean differences [SMD] = –3.10; 95% confidence interval [CI]: –3.40 to –2.79; I2 = 99%; p < 0.001). Lower LDH levels were observed in non-severe groups compared to severe course of COVID-19 (SMD = –2.38; 95% CI: –2.61 to –2.14; I2 = 99%; p < 0.001). The level of LDH was statistically significantly lower in the severe group compared to the critical group (SMD = –1.48; 95% CI: –2.04 to –0.92; I2 = 98%; p < 0.001). Patients who did not require treatment in the intensive care unit (ICU) showed significantly lower levels of LDH compared to patients who required treatment in the ICU (SMD = –3.78; 95% CI: –4.48 to –3.08; I2 = 100%; p < 0.001). Conclusions: This meta-analysis showed that elevated LDH was associated with a poor outcome in COVID-19.

13 April 2021 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
Aleksandra GąseckaAleksandra Gąsecka
Aleksandra Gąsecka
MPMichał Pruc
Michał Pruc
KKKatarzyna Kukula
Katarzyna Kukula
NGNatasza Gilis-Malinowska
Natasza Gilis-Malinowska
Krzysztof J. FilipiakKrzysztof J. Filipiak
Krzysztof J. Filipiak
Lukasz SzarpakLukasz Szarpak
Lukasz Szarpak

23 February 2022 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
Lukasz SzarpakLukasz Szarpak
Lukasz Szarpak
MPMichal Pruc
Michal Pruc
Krzysztof J. FilipiakKrzysztof J. Filipiak
Krzysztof J. Filipiak
JPJulia Popieluch
Julia Popieluch
ABAndrzej Bielski
Andrzej Bielski
FPFrank W. Peacock
Frank W. Peacock

7 April 2022 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
Krzysztof J. FilipiakKrzysztof J. Filipiak
Krzysztof J. Filipiak
Aleksandra GąseckaAleksandra Gąsecka
Aleksandra Gąsecka
WGWladyslaw Gawel
Wladyslaw Gawel
DKDorota Koziel
Dorota Koziel
MJMilosz J. Jaguszewski
Milosz J. Jaguszewski
ZRZubaid Rafique
Zubaid Rafique
Background: Vitamin D is a likely candidate for treatment as its immune modulating characteristics have effects on coronavirus disease 2019 (COVID-19) patients. It was sought herein, to summarize the studies published to date regarding the vitamin D supplementation to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients. Methods: A systematic review and meta-analysis were performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The primary outcome were 14-day and in-hospital mortality reported as an odds ratio (OR) with the associated 95% confidence interval (CI). Results: Eight articles were included in the review with a combined total of 2,322 individual patients, 786 in the vitamin D supplementation group and 1,536 in the control group. The use of vitamin D compared to the group without vitamin D supplementation was associated with a lower 14-day mortality (18.8% vs. 31.3%, respectively; OR = 0.51; 95% CI: 0.12–2.19; p = 0.36), a lower in-hospital mortality (5.6% vs. 16.1%; OR = 0.56; 95% CI: 0.23–1.37; I2 = 74%; p = 0.20), the rarer intensive care unit admission (6.4% vs. 23.4%; OR = 0.19; 95% CI: 0.06–0.54; I2 = 77%; p = 0.002) as well as rarer mechanical ventilation (6.5% vs. 18.9%; OR = 0.36; 95% CI: 0.16–0.80; I2 = 0.48; p = 0.01). Conclusions: Vitamin D supplementation in SARS-CoV-2 positive patients has the potential to positively impact patients with both mild and severe symptoms. As several high-quality randomized control studies have demonstrated a benefit in hospital mortality, vitamin D should be considered a supplemental therapy of strong interest. Should vitamin D prove to reduce hospitalization rates and symptoms outside of the hospital setting, the cost and benefit to global pandemic mitigation efforts would be substantial. Background: Vitamin D is a likely candidate for treatment as its immune modulating characteristics have effects on coronavirus disease 2019 (COVID-19) patients. It was sought herein, to summarize the studies published to date regarding the vitamin D supplementation to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients. Methods: A systematic review and meta-analysis were performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The primary outcome were 14-day and in-hospital mortality reported as an odds ratio (OR) with the associated 95% confidence interval (CI). Results: Eight articles were included in the review with a combined total of 2,322 individual patients, 786 in the vitamin D supplementation group and 1,536 in the control group. The use of vitamin D compared to the group without vitamin D supplementation was associated with a lower 14-day mortality (18.8% vs. 31.3%, respectively; OR = 0.51; 95% CI: 0.12–2.19; p = 0.36), a lower in-hospital mortality (5.6% vs. 16.1%; OR = 0.56; 95% CI: 0.23–1.37; I2 = 74%; p = 0.20), the rarer intensive care unit admission (6.4% vs. 23.4%; OR = 0.19; 95% CI: 0.06–0.54; I2 = 77%; p = 0.002) as well as rarer mechanical ventilation (6.5% vs. 18.9%; OR = 0.36; 95% CI: 0.16–0.80; I2 = 0.48; p = 0.01). Conclusions: Vitamin D supplementation in SARS-CoV-2 positive patients has the potential to positively impact patients with both mild and severe symptoms. As several high-quality randomized control studies have demonstrated a benefit in hospital mortality, vitamin D should be considered a supplemental therapy of strong interest. Should vitamin D prove to reduce hospitalization rates and symptoms outside of the hospital setting, the cost and benefit to global pandemic mitigation efforts would be substantial.

21 November 2020 in Polish Archives of Internal Medicine
Verified
Journal Article
Open access
Lukasz SzarpakLukasz Szarpak
Lukasz Szarpak
BNBlazej Nowak
Blazej Nowak
DKDariusz Kosior
Dariusz Kosior
AZArtur Zaczyński
Artur Zaczyński
Krzysztof J. FilipiakKrzysztof J. Filipiak
Krzysztof J. Filipiak
MJMilosz Jaroslaw Jaguszewski
Milosz Jaroslaw Jaguszewski

20 February 2025 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
MPMichal Pruc
Michal Pruc
DŚDamian Świeczkowski
Damian Świeczkowski
BCBasar Cander
Basar Cander
MJMilosz J. Jaguszewski
Milosz J. Jaguszewski
SGSagar Galwankar
Sagar Galwankar
Lukasz SzarpakLukasz Szarpak
Lukasz Szarpak
Background: The role of Cystatin C (CysC) in the diagnosis and prognosis of cardiovascular disease, particularly acute coronary syndrome (ACS), is increasingly significant. The goal of this meta-analysis was to assess the diagnostic and prognostic value of CysC in patients with ACS, as well as its association with major adverse cardiovascular events (MACE), defined as mortality, myocardial infarction, heart failure, and stroke. Methods: The present study is a systematic review and meta-analysis. Using PubMed, Web of Science, Cochrane Library, and Embase, a literature review of cohort and case control studies reporting MACE and using the terms ACS and Cystatin C was conducted, excluding studies published after August 1, 2024. the meta-analysis using a random effects model. Results: CysC concentrations were significantly higher in patients with ACS compared to controls [mean difference (MD) = 0.36, p < 0.001], and in acute myocardial infarction (AMI) vs. unstable angina (MD = 0.18, p < 0.001). No significant differences were observed between ST elevation myocardial infarction (STEMI) and Non-ST elevation myocardial infarction (NSTEMI). Patients with MACE had higher CysC levels than those without (MD = 0.25, p < 0.001). Hospital survivors had lower CysC levels compared to those who died (MD = −0.25, p < 0.001). Higher CysC concentrations were associated with increased risks of MACE, cardiac death, overall mortality, myocardial reinfarction, and stroke, both during hospitalization and beyond. Conclusions: CysC is a promising biomarker for both diagnosis and prognosis in patients with ACS, especially in the context of predicting MACE, mortality and heart failure risk. The use of CysC may improve risk stratification and support therapeutic decision-making in clinical practice. Keywords: cystatin C biomarker prognosis diagnosis ACS acute coronary syndrome meta-analysis